The expression and clinical significance of CA125, CEA and CYFRA21-1 in the treatment of advanced non-small cell lung cancer with bevacizumab combined with TP chemotherapy

Objective: To investigate the expression and clinical significance of CA125, CEA and CYFRA21-1 in the treatment of advanced non-small cell lung cancer with bevacizumab combined with TP chemotherapy. Methods: A total of 90 advanced NSCLC patients diagnosed in our hospital from January 2015 to December 2016 were selected as study subjects. All patients were given bevacizumab combined with TP chemotherapy for 2 courses. Venous blood was collected before and after chemotherapy and tested using chemiluminescence method for serum CA125, CEA and CYFRA21-1 content. The changes of the three indicators before and after chemotherapy were evaluated and the association between the changes and chemotherapeutic effect were evaluated. Results: Before chemotherapy, the positive rate of CA125, CEA and CYFRA21-1 in clinical stage IV patients, the pathological type of adenocarcinoma patients and metastatic sites more than 2 were significantly higher than those of clinical stage III patients, the pathological type of squamous cell carcinoma and metastatic sites 1. The differences were statistically significant (P < 0.05). After chemotherapy, the levels of CA125, CEA, and CYFRA21-1 in patients with clinical efficacy of cure (CR) and partial remission (PR) were significantly lower than those before chemotherapy, and the differences were statistically significant (P < 0.05). After chemotherapy, the levels of CA125, CEA and CYFRA21-1 in patients with disease progression (PD) significantly increased (P < 0.05). The overall agreement rates of clinical efficacy of CA125, CEA and CYFRA21-1 and clinical efficacy of tumor were 27.8%, 46.7% and 51.1% respectively. Conclusion: The changes of CA125, CEA and CYFRA21-1 levels are positively related to the clinical efficacy of NSCLC after chemotherapy. The three indicators are worthy to be used in clinical. (author)